ArticleBlood advances2026
Metabolic profiling and perturbations of human CD34+ hematopoietic stem and progenitor cells to regulate HSPC function.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractHematopoietic stem cells (HSCs) possess self-renewal and multilineage differentiation abilities to generate blood cells and sustain hematopoiesis. Recent studies indicate that HSC metabolism is crucial for regulating their function and cell fate determination in mammals. However, a comprehensive understanding of the metabolic landscape of human HSCs across distinct developmental stages remains lacking. In this study, we performed untargeted metabolomics of lin-CD34+ hematopoietic stem and progenitor cells (HSPCs) from human fetal liver, umbilical cord blood, and adult bone marrow, revealing different developmentally associated metabolic signatures that may shape HSPC function across ontogeny. Metabolomic analysis identified d-glutamine (Gln) and arachidonic acid (AA) as metabolites exhibiting distinct abundance during HSPC development, suggesting their potential roles in modulating HSPC function. Transcriptomic profiling after specific metabolic treatments further revealed distinct gene expression programs associated with lineage commitment, stemness maintenance, and metabolic regulation. Functional assays demonstrated that inhibition of Gln metabolism with DON (6-diazo-5-oxo-l-norleucine) induced HSPCs into quiescent cell states, improving the engraftment of HSPCs and myeloid differentiation. In contrast, exogenous AA supplementation in HSPC culture promoted proliferation and significantly enhanced megakaryocytic differentiation both in vitro and in vivo. Collectively, our study profiled the metabolic landscape of human HSPCs from embryonic to adult period through the newborn stages, suggesting that metabolic modulation could regulate HSPC function. These findings provide novel mechanistic insights and potential strategies for metabolite-based interventions to promote and enhance human HSPC function, with broad implications for basic research and regenerative medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.